Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells

Journal of Thoracic Oncology

Volumn 8, Issue 8, 2013, Pages 1032-1042

  Kobold, Sebastian ^a   Völk, Stefanie ^a   Clauditz, Till ^b   Küpper, Natascha Jennifer ^a   Minner, Sarah ^b   Tufman, Amanda ^c   Düwell, Peter ^a   Lindner, Michael ^d   Koch, Ina ^d   Heidegger, Simon ^a   Rothenfuer, Simon ^a   Schnurr, Max ^a   Huber, Rudolf Maria ^c   Wilczak, Waldemar ^b   Endres, Stefan ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Thoracic Oncology Center   (Germany)

^d Comprehensive Pneumology Center Munich   (Germany)

Author keywords

Interleukin 22; Interleukin 22 receptor 1; Large cell lung cancer; Lung cancer; Small cell lung cancer

Indexed keywords

CISPLATIN; INTERLEUKIN 22;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CELL PROLIFERATION; CHILD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LUNG CANCER; LUNG CARCINOMA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; UPREGULATION; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CELL LINE, TUMOR; CHILD; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, INTERLEUKIN; SMALL CELL LUNG CARCINOMA;

EID: 84880923452     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31829923c8     Document Type: Article

References (32)

1. Vivier E, Spits H, Cupedo T. Interleukin-22-producing innate immune cells: new players in mucosal immunity and tissue repair? Nat Rev Immunol 2009;9:229-234.
2. Wolk K, Witte E, Witte K, Warszawska K, Sabat R. Biology of interleukin-22. Semin Immunopathol 2010;32:17-31.
3. Hoegl S, Bachmann M, Scheiermann P, et al. Protective properties of inhaled IL-22 in a model of ventilator-induced lung injury. Am J Respir Cell Mol Biol 2011;44:369-376.
4. Chestovich PJ, Uchida Y, Chang W, et al. Interleukin-22: implications for liver ischemia-reperfusion injury. Transplant 2012;93:485-492.
5. Eyerich S, Eyerich K, Pennino D, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009;119:3573-3585.
6. Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld JC. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 2002;277:33676-33682.
7. Zhang W, Chen Y, Wei H, et al. Antiapoptotic activity of autocrine interleukin- 22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res 2008;14:6432-6439.
8. Curd LM, Favors SE, Gregg RK. Pro-tumour activity of interleukin- 22 in HPAFII human pancreatic cancer cells. Clin Exp Immunol 2012;168:192-199.
9. Whittington HA, Armstrong L, Uppington KM, Millar AB. Interleukin-22: a potential immunomodulatory molecule in the lung. Am J Respir Cell Mol Biol 2004;31:220-226.
10. Simonian PL, Wehrmann F, Roark CL, Born WK, O'Brien RL, Fontenot AP. Gammadelta T cells protect against lung fibrosis via IL-22. J Exp Med 2010;207(10):2239-53.
11. Kumar P, Thakar MS, Ouyang W, Malarkannan S. IL-22 from conventional NK cells is epithelial regenerative and inflammation protective during influenza infection. Mucosal Immunol 2013;6:69-82.
12. Nagalakshmi ML, Rascle A, Zurawski S, Menon S, de Waal Malefyt R. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol 2004;4:679-691.
13. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4:844-847.
14. Merseburger AS, Hennenlotter J, Simon P, et al. Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. Anticancer Res 2005;25(3B):1901-1907.
15. Tian F, Schrödl K, Kiefl R, Huber RM, Bergner A. The hedgehog pathway inhibitor GDC-0449 alters intracellular Ca2+ homeostasis and inhibits cell growth in cisplatin-resistant lung cancer cells. Anticancer Res 2012;32:89-94.
16. Lazar MH, Christensen PJ, Du M, et al. Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin. Am J Respir Cell Mol Biol 2004;31:672-678.
17. Kobold S, Tams S, Luetkens T, et al. Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation. Clin Dev Immunol 2011;2011:302145.
18. Huber S, Gagliani N, Zenewicz LA, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012;491:259-263.
19. Xing WW, Zou MJ, Liu S, Xu T, Wang JX, Xu DG. Interleukin-22 protects against acute alcohol-induced hepatotoxicity in mice. Biosci Biotechnol Biochem 2011;75:1290-1294.
20. Cherfils-Vicini J, Platonova S, Gillard M, et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 2010;120:1285-1297.
21. Baird AM, Gray SG, O'Byrne KJ. IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF. Eur J Cancer 2011;47:1908-1918.
22. Tohyama M, Yang L, Hanakawa Y, Dai X, Shirakata Y, Sayama K. IFN-aα enhances IL-22 receptor expression in keratinocytes: a possible role in the development of psoriasis. J Invest Dermatol 2012;132:1933-1935.
23. Brand S, Beigel F, Olszak T, et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006;290:G827-G838.
24. Uva P, Lahm A, Sbardellati A, Grigoriadis A, Tutt A, de Rinaldis E. Comparative Membranome expression analysis in primary tumors and derived cell lines. PLoS One 2010;5:e11742.
25. Ye ZJ, Zhou Q, Yin W, et al. Interleukin 22-producing CD4+ T cells in malignant pleural effusion. Cancer Lett 2012;326:23-32.
26. Zhuang Y, Peng LS, Zhao YL, et al. Increased intratumoral IL-22- producing CD4(+) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival. Cancer Immunol Immunother 2012;61:1965-1975.
27. Jiang R, Tan Z, Deng L, et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatol 2011;54:900-909.
28. Koyama K, Kagamu H, Miura S, et al. Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res 2008;14:6770-6779.
29. Kumar P, Thakar MS, Ouyang W, Malarkannan S. IL-22 from conventional NK cells is epithelial regenerative and inflammation protective during influenza infection. Mucosal Immunol 2013;6:69-82.
30. Cowan J, Pandey S, Filion LG, Angel JB, Kumar A, Cameron DW. Comparison of interferon-gamma-, interleukin (IL)-17- and IL-22- expressing CD4 T cells, IL-22-expressing granulocytes and proinflammatory cytokines during latent and active tuberculosis infection. Clin Exp Immunol. 2012;167(2):317-29.
31. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
32. Kotlarz D, Beier R, Murugan D, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterol 2012;143:347-355.